Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2581

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2581
---
 our product candidates;

    ●
    general
    market conditions or extraordinary external events, such as recessions, natural disasters, and/or the conflict between Russia and
    Ukraine;

    ●
    the
    changing and volatile U.S. and global socio-economic and political environments; and

    ●
    future
    accounting pronouncements or changes in our accounting policies or changes in tax laws.

The
cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results.
As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability
could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue
or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if
the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline
substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.

75

Risks
Related to Clinical Development

We
are a biopharmaceutical company with a limited operating history, and many of our development programs are in early stages of development.
This may make it difficult to evaluate our prospects and likelihood of success.

We
are an early-stage biopharmaceutical company with a limited operating history, have no products approved for commercial sale and have
not generated any revenue. All of our product candidates are in the preclinical stages of development and will require additional preclinical
studies or clinical development as well as regulatory review and approval, substantial investment, access to sufficient commercial manufacturing
capacity and significant marketing efforts before we can generate any revenue from product sales. Our operations to date have been limited
to organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and performing
research and development of our product candidates. Our approach to the discovery and development of product candidates is unproven,
and we do not know whether we will be able to develop any products of commercial value. In addition, our product candidates will require
substantial additional development and clinical research time and resources before we would be able to apply for or receive regulatory
approvals and begin generating revenue from product sales. We have not yet demonstrated the ability to initiate or progress any product
candidate through clinical trials. We are still in preclinical development and may be